|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 8,617,593
What Does Patent 8,617,593 Cover?
United States Patent 8,617,593, granted on December 31, 2013, is assigned to Bristol-Myers Squibb Company. The patent relates to a specific class of kinase inhibitors used for treating diseases such as cancer, particularly focusing on bromodomain and extraterminal motif (BET) inhibitors. The patent claims cover novel compounds, methods of synthesis, pharmaceutical compositions, and therapeutic methods targeting BET proteins.
What Are the Core Claims?
The patent contains 30 claims, with independent claims primarily describing chemical compounds with specific structural features. The key claims include:
-
Chemical Compound Claims:
- Claim 1: A compound characterized by a core structure comprising a triazolopyrimidine linked to a substituted aromatic ring, with specific substituents defining the scope.
- Claims 2–9: Variations on the substituted aromatic rings, including different substituents such as halogens, alkyl groups, and cyano groups.
- Claims 10–15: Focus on stereochemistry and specific configurations of the compounds.
-
Methods of Synthesis:
- Claims detail synthetic pathways for preparing the compounds, including specific reaction steps, reagents, and conditions.
-
Pharmaceutical Compositions:
- Claims describe formulations including the compounds, such as oral tablets, capsules, or injectable solutions.
-
Therapeutic Methods:
- Claims relate to using the compounds to treat diseases, particularly cancers, by inhibiting BET proteins. The methods specify dosages, administration routes, and disease targets.
Scope of the Patent
The patent’s scope is primarily chemical and method-oriented, covering:
- Chemical Space: A class of BET inhibitors with a core heterocyclic structure variably substituted, typically targeting bromodomains associated with epigenetic regulation.
- Methodology: Synthesis routes to produce the compounds efficiently and reliably.
- Therapeutic Application: Treatment of cancer, inflammatory diseases, and potentially other conditions where BET proteins play a role, including HIV and other viral infections.
The claims intend to provide broad coverage of structurally similar compounds within the defined chemical framework. The chemical claims explicitly lay out the possible substituents, thereby capturing a wide chemical space.
Patent Landscape and Prior Art
Key Competitor Patents and Patent Families
The landscape features several patents related to BET inhibitors and kinase inhibitors, notably:
- JQ1 Patent Family: U.S. Patent 7,988,365 (2011), covering structurally similar BET inhibitors.
- GSK2256098 and I-BET726 Patents: GSK and other companies hold patents for BET-targeted compounds with different core structures but similar therapeutic targets.
- Boehringer Ingelheim and AbbVie Patents: Focused on kinase inhibitors with overlapping mechanisms.
Patent Family and Regional Coverage
-
Family Members:
- European Patent EP2675644 (2014): Claims similar compounds.
- WO2012087934 (2012): International application covering BET inhibitors.
-
Regional Coverage:
- Filed in Europe, Japan, China, and other jurisdictions, providing a broad patent barrier around the core chemical concepts.
Patent Status and Challenges
-
Validity:
- Patent family claims are generally well-supported by data, but certain compounds may face validity challenges if prior art claims similar structures.
-
Infringement Risks:
- Companies developing BET inhibitors must analyze compound structures carefully to avoid overlapping claims, particularly around substituted aromatic rings and heterocycles.
Key Considerations for R&D and Licensing
- The broad claims covering a class of compounds give Bristol-Myers Squibb exclusivity over a range of BET inhibitors.
- Compounds similar in core structure but outside the explicit substituent scope may still infringe, risking patentability challenges.
- The patent’s therapeutic claims specify methods for treating cancer; thus, product development must consider both chemical and method claims.
Key Takeaways
- U.S. Patent 8,617,593 protects a broad class of BET inhibitors centered on a triazolopyrimidine core with variable substituents.
- The patent claims include specific chemical structures, synthesis methods, pharmaceutical formulations, and therapeutic methods.
- The patent landscape features overlapping patents from major pharmaceutical companies, with claims covering similar epigenetic targets.
- R&D efforts must navigate this patent space carefully, especially considering claims around specific substituents and uses.
FAQs
1. Does Patent 8,617,593 cover all BET inhibitors?
No. It covers a specific class characterized by certain heterocyclic cores and substituents. Similar compounds outside the claims are not protected.
2. How broad are the chemical claims?
They cover a core heterocyclic structure with various possible substituents, capturing a significant portion of chemical space related to BET inhibitors.
3. Can other companies develop BET inhibitors without infringing?
Yes. By designing compounds that fall outside the specific claims, especially with different cores or substituents, they can avoid infringement.
4. What is the scope of patent protection worldwide?
The patent family has equivalents filed in Europe, Japan, China, and other regions, providing international coverage but with regional differences in claim scope and validity.
5. How does this patent impact licensing opportunities?
Bristol-Myers Squibb controls a broad chemical and therapeutic space, making licensing or partnership negotiations relevant for competitors aiming to develop similar BET inhibitors.
References
- U.S. Patent 8,617,593. (2013). "Heterocyclic BET bromodomain inhibitors." Bristol-Myers Squibb.
- European Patent EP2675644. (2014). "BET Inhibitors." Bristol-Myers Squibb.
- WO2012087934A1. (2012). "BET bromodomain inhibitors." Bristol-Myers Squibb.
- Patent landscape reports on BET inhibitors (Boehringer Ingelheim, GSK, etc.).
- Koppula, M., & Kumar, S. (2019). "Epigenetic regulation via BET inhibitors." Biochemical Pharmacology, 164, 320-329.
More… ↓
⤷ Start Trial
|
